Because FDA/NICE approved IL1β inhibitors, Canakinumab and Anakinra, have poor oral bioavailability making administration difficult for patients (subcutaneous injection), we also assessed the ability of the orally available IL1β inhibitor, MLX01, to inhibit the metastatic outgrowth of breast tumours following oral administration (Figure S6A). Here, IL1B is linked to breast neoplasm.